Resistant H1N1 Goes to Summer Camp

Kemper, Carol A.
October 2009
Infectious Disease Alert;Oct2009, Vol. 29 Issue 1, p11
The article focuses on the existence of H1N1 viral infection resistant to oseltamivir at a summer camp in North Carolina during an outbreak in June 2009. It references the article "Oseltamivir-Resistant Pandemic Influenza A (H1N1) 2009 Virus Infection in 2 Summer Campers Receving Prophylaxis - North Carolina" in the September 2009 issue of "MMWR." A teenage girl, who had just completed a 10-day course of oseltamivir chemoprophylaxis, was again exposed to influenza, prompting a second course of the drug at a higher dose.


Related Articles

  • Oseltamivir-Resistant 2009 Pandemic Influenza A (H1N1) Virus Infection in Two Summer Campers Receiving Prophylaxis -- North Carolina, 2009. Garrison, M.; Weldon, L.; Brantley, P.; Wolf, L.; Davies, M.; Maillard, J.-M.; Moore, Z.; Sheu, T.; Deyde, V.; Gubareva, L.; Fry, A. M.; Fleischauer, A.; Dailey, N. J. // MMWR: Morbidity & Mortality Weekly Report;9/11/2009, Vol. 58 Issue 35, p969 

    The article reports on two girls in a summer camp in North Carolina contacting influenza A(H1N1) virus resistant to oseltamivir, a neurominidase inhibitor commonly used for medication and chemoprophylaxis. In this case, the occurrence of an oseltamivir resistant A(H1N1) virus cannot be...

  • 2009H1N1 Influenza in Immunocompetent and Immunocompromised Patients. Moss, Ronald B. // Infectious Diseases: Research & Treatment;2012, Issue 5, p33 

    The treatment and prevention of influenza virus infection has been associated with two major challenges that are exemplified by 2009H1N1 as well as previous pandemics. The constant evolutionary pressure on the influenza virus can result in novel strains which may not be optimally protected by...

  • Responding to pandemic (H1N1) 2009 influenza: the role of oseltamivir. Reddy, David // Journal of Antimicrobial Chemotherapy (JAC);Apr2010 Supplement 2, Vol. 65 Issue suppl_2, pii35 

    Pandemic (H1N1) 2009 influenza is affecting countries in all five continents, with most cases so far having been reported in North and South America and Europe, and children and young adults being the most susceptible age groups. To date, the clinical course of disease is typically mild, with...

  • Targeting pandemic influenza: a primer on influenza antivirals and drug resistance. Moss, Ronald B.; Davey, Richard T.; Steigbigel, Roy T.; Fang Fang // Journal of Antimicrobial Chemotherapy (JAC);Jun2010, Vol. 65 Issue 6, p1086 

    The emergence of the 2009 H1N1 pandemic influenza A virus, as well as constant antigenic drift of seasonal influenza, underscores the remarkable versatility of this virus in adapting to the human population. While vaccines are the principal public health defence against influenza, rapid vaccine...

  • Alternative Therapeutic Options for Pandemic Influenza A H1N1. Tien, Pamela; Nieh, Jonathan; Song, Jessica C. // Infectious Disease Alert;Jan2010, Vol. 29 Issue 4, p39 

    The article discusses alternative therapeutic options for addressing pandemic influenza A H1N1. It notes that tests made on the pandemic influenza A H1N1 virus isolates have yielded results showing 100% resistance to certain antiviral agents as well as over 99% susceptibility rate to the...

  • Swine Flu (H1N1) update 2010. Amerena, Vincent C. // eLABORATE;Jan/Feb2010, p116 

    The article provides updated information through January 1, 2010 on the H1N1 influenza. The virus is transmitted from human to human, and countries are no longer required to report cases to the World Health Organization (WHO). Antiviral drug resistance, water contamination of the drug ostelamvir...

  • H1N1 2009 Pandemic Influenza Virus: Resistance of the I223R Neuraminidase Mutant Explained by Kinetic and Structural Analysis. Van Der Vries, Erhard; Collins, Patrick J.; Vachieri, Sebastien G.; Xiaoli Xiong; Junfeng Liu; Walker, Philip A.; Haire, Lesley F.; Hay, Alan J.; Schutten, Martin; Osterhaus, Albert D. M. E.; Martin, Steve R.; Boucher, Charles A. B.; Skehel, John J.; Gamblin, Steve J. // PLoS Pathogens;Sep2012, Vol. 8 Issue 9, Special section p1 

    Two classes of antiviral drugs, neuraminidase inhibitors and adamantanes, are approved for prophylaxis and therapy against influenza virus infections. A major concern is that antiviral resistant viruses emerge and spread in the human population. The 2009 pandemic H1N1 virus is already resistant...

  • Drug resistant swine flu emerges.  // New Scientist;7/4/2009, Vol. 203 Issue 2715, p6 

    The article focuses on the first case of H1N1 swine flu resistant to antiviral drug Tamiflu. The patient was in contact with an infected person and was given low-dose Tamiflu as a precaution, but she still developed flu. Such patient recovered after receiving antiviral Relenza. The author notes...

  • Environmental Levels of the Antiviral Oseltamivir Induce Development of Resistance Mutation H274Y in Influenza A/H1N1 Virus in Mallards. Järhult, Josef D.; Muradrasoli, Shaman; Wahlgren, John; Söderström, Hanna; Orozovic, Goran; Gunnarsson, Gunnar; Bröjer, Caroline; Latorre-Margalef, Neus; Fick, Jerker; Grabic, Roman; Lennerstrand, Johan; Waldenström, Jonas; Lundkvist, Åke; Olsen, Björn // PLoS ONE;2011, Vol. 6 Issue 9, p1 

    Oseltamivir (Tamiflu®) is the most widely used drug against influenza infections and is extensively stockpiled worldwide as part of pandemic preparedness plans. However, resistance is a growing problem and in 2008-2009, seasonal human influenza A/H1N1 virus strains in most parts of the world...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics